Download PDF
Dtsch Med Wochenschr 2016; 141(24): 1789-1792
DOI: 10.1055/s-0042-117625
Klinischer Fortschritt
Verdauungs- und Stoffwechselerkrankungen
© Georg Thieme Verlag KG Stuttgart · New York

Neues zur Therapie der chronisch-entzündlichen Darmerkrankungen

Novel therapeutic approaches in inflammatory bowel diseases
Raja Atreya
1   Medizinische Klinik 1, Friedrich-Alexander-Universität Erlangen-Nürnberg
,
Markus Friedrich Neurath
1   Medizinische Klinik 1, Friedrich-Alexander-Universität Erlangen-Nürnberg
› Author Affiliations
Further Information

Publication History

Publication Date:
30 November 2016 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Durch ein verbessertes Verständnis der multifaktoriellen Immunpathogenese der CED konnten in den letzten Jahren zahlreiche neue Substanzen entwickelt oder bereits zur Therapie von Morbus Crohn oder Colitis ulcerosa zugelassen werden. Diese umfassen z. B. Antikörper gegen IL-12 / 23, anti-Adhäsionsmolekül-Antikörper und Antisense-Oligonukleotide. Die Vielzahl der zukünftig verfügbaren Therapien wird zu einer Veränderung der aktuell angewandten Therapiealgorithmen führen. Marker für eine verbesserte individualisierte Therapieentscheidung werden für eine effektivere Behandlung von CED-Patienten dringend benötigt.

Abstract

Increasing knowledge regarding the immunopathogenesis of IBD has led to the development or approval of novel therapeutic agents for the treatment of Crohn’s disease or ulcerative colitis. The new substances for example include antibodies against IL-12 / 23, anti-adhesion molecules and antisense oligonucleotides. The increase of therapeutic options will lead to a change of currently used therapeutic algorithms. Biomarkers to ensure a more individualized therapeutic approach are urgently needed to improve an efficient therapy of IBD patients.

Schlüsselwörter

Morbus Crohn - Colitis ulcerosa - Biologika - Oligonukleotide

Keywords

Crohn’s disease - ulcerative colitis - biologicals - oligonucleotides
 

  • Literatur

  • 1 Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63 (3) 433-441
    CrossrefPubMedGoogle Scholar
  • 2 European Medicines Agency Questions and answers on biosimilar medicines (similar biological medicinal products). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf
    PubMedGoogle Scholar
  • 3 Gecse KB, Lovász BD, Farkas K et al. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre Nationwide Cohort. J Crohns Colitis 2016; 10 (2) 133-140
    CrossrefPubMedGoogle Scholar
  • 4 Smits LJ, Derikx LA, de Jong DJ et al. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J Crohns Colitis 2016 Apr 19. pii: jjw087. [Epub ahead of print]
    PubMed
  • 5 Sandborn WJ, Feagan BG, Rutgeerts P et al. GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369 (8) 711-721
    PubMedGoogle Scholar
  • 6 Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147 (3) 618-627
    CrossrefPubMedGoogle Scholar
  • 7 Feagan BG, Rutgeerts P, Sands BE et al. GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369 (8) 699-710
    PubMedGoogle Scholar
  • 8 Colombel JF, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2016 Feb 18. pii: gutjnl-2015-311079
    PubMed
  • 9 Vermeire S, O’Byrne S, Keir M et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014; 384 9940 309-318
    CrossrefPubMedGoogle Scholar
  • 10 Sandborn WJ, Ghosh S, Panes J et al. Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367 (7) 616-624
    PubMedGoogle Scholar
  • 11 Monteleone G, Neurath MF, Ardizzone S et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 2015; 372 (12) 1104-1113
    CrossrefPubMedGoogle Scholar
  • 12 Sandborn WJ, Gasink C, Gao LL et al. CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367 (16) 1519-1528
    PubMedGoogle Scholar
  • 13 Feagan B, Gasink C, Lang Y et al. OP054-LB4 A multicenter, double-blind, placebo-controlled Ph3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naïve or not refractory to anti-TNFa: UNITI-2 (abstract). United European Gastroenterol J 2015; 3 (6) 2
    Google Scholar
  • 14 Sandborn W, Feagan BG, Gasink C et al. 768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate-Severe Crohn’s Disease Patients: Results From IM-UNITI (abstract). Gastroenterology 2016; 150 (4) S157-S158
    Google Scholar
  • 15 Atreya R, Neumann H, Neufert C et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 2014; 20 (3) 313-318
    CrossrefPubMedGoogle Scholar